Designing allosteric regulators of thrombin. Monosulfated benzofuran dimers selectively interact with Arg173 of exosite 2 to induce inhibition

May H. Abdel Aziz, Preetpal Singh Sidhu, Aiye Liang, Ji Yeong Kim, Philip D. Mosier, Qibing Zhou, David Farrell, Umesh R. Desai

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Earlier, we reported on the design of sulfated benzofuran dimers (SBDs) as allosteric inhibitors of thrombin (Sidhu et al. J. Med. Chem.201154 5522-5531). To identify the site of binding of SBDs, we studied thrombin inhibition in the presence of exosite 1 and 2 ligands. Whereas hirudin peptide and heparin octasaccharide did not affect the IC 50 of thrombin inhibition by a high affinity SBD, the presence of full-length heparin reduced inhibition potency by 4-fold. The presence of γ′ fibrinogen peptide, which recognizes Arg93, Arg97, Arg173, Arg175, and other residues, resulted in a loss of affinity that correlated with the ideal Dixon-Webb competitive profile. Replacement of several arginines and lysines of exosite 2 with alanine did not affect thrombin inhibition potency, except for Arg173, which displayed a 22-fold reduction in IC 50. Docking studies suggested a hydrophobic patch around Arg173 as a plausible site of SBD binding to thrombin. The absence of the Arg173-like residue in factor Xa supported the observed selectivity of inhibition by SBDs. Cellular toxicity studies indicated that SBDs are essentially nontoxic to cells at concentrations as high as 250 mg/kg. Overall, the work presents the localization of the SBD binding site, which could lead to allosteric modulators of thrombin that are completely different from all clinically used anticoagulants.

Original languageEnglish (US)
Pages (from-to)6888-6897
Number of pages10
JournalJournal of Medicinal Chemistry
Volume55
Issue number15
DOIs
StatePublished - Aug 9 2012

Fingerprint

Thrombin
Heparin
Binding Sites
Hirudins
Peptides
Factor Xa
benzofuran
Alanine
Anticoagulants
Fibrinogen
Lysine
Arginine
Ligands

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Designing allosteric regulators of thrombin. Monosulfated benzofuran dimers selectively interact with Arg173 of exosite 2 to induce inhibition. / Abdel Aziz, May H.; Sidhu, Preetpal Singh; Liang, Aiye; Kim, Ji Yeong; Mosier, Philip D.; Zhou, Qibing; Farrell, David; Desai, Umesh R.

In: Journal of Medicinal Chemistry, Vol. 55, No. 15, 09.08.2012, p. 6888-6897.

Research output: Contribution to journalArticle

Abdel Aziz, May H. ; Sidhu, Preetpal Singh ; Liang, Aiye ; Kim, Ji Yeong ; Mosier, Philip D. ; Zhou, Qibing ; Farrell, David ; Desai, Umesh R. / Designing allosteric regulators of thrombin. Monosulfated benzofuran dimers selectively interact with Arg173 of exosite 2 to induce inhibition. In: Journal of Medicinal Chemistry. 2012 ; Vol. 55, No. 15. pp. 6888-6897.
@article{5c05dfe911704f858617c1d91af15140,
title = "Designing allosteric regulators of thrombin. Monosulfated benzofuran dimers selectively interact with Arg173 of exosite 2 to induce inhibition",
abstract = "Earlier, we reported on the design of sulfated benzofuran dimers (SBDs) as allosteric inhibitors of thrombin (Sidhu et al. J. Med. Chem.201154 5522-5531). To identify the site of binding of SBDs, we studied thrombin inhibition in the presence of exosite 1 and 2 ligands. Whereas hirudin peptide and heparin octasaccharide did not affect the IC 50 of thrombin inhibition by a high affinity SBD, the presence of full-length heparin reduced inhibition potency by 4-fold. The presence of γ′ fibrinogen peptide, which recognizes Arg93, Arg97, Arg173, Arg175, and other residues, resulted in a loss of affinity that correlated with the ideal Dixon-Webb competitive profile. Replacement of several arginines and lysines of exosite 2 with alanine did not affect thrombin inhibition potency, except for Arg173, which displayed a 22-fold reduction in IC 50. Docking studies suggested a hydrophobic patch around Arg173 as a plausible site of SBD binding to thrombin. The absence of the Arg173-like residue in factor Xa supported the observed selectivity of inhibition by SBDs. Cellular toxicity studies indicated that SBDs are essentially nontoxic to cells at concentrations as high as 250 mg/kg. Overall, the work presents the localization of the SBD binding site, which could lead to allosteric modulators of thrombin that are completely different from all clinically used anticoagulants.",
author = "{Abdel Aziz}, {May H.} and Sidhu, {Preetpal Singh} and Aiye Liang and Kim, {Ji Yeong} and Mosier, {Philip D.} and Qibing Zhou and David Farrell and Desai, {Umesh R.}",
year = "2012",
month = "8",
day = "9",
doi = "10.1021/jm300670q",
language = "English (US)",
volume = "55",
pages = "6888--6897",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "15",

}

TY - JOUR

T1 - Designing allosteric regulators of thrombin. Monosulfated benzofuran dimers selectively interact with Arg173 of exosite 2 to induce inhibition

AU - Abdel Aziz, May H.

AU - Sidhu, Preetpal Singh

AU - Liang, Aiye

AU - Kim, Ji Yeong

AU - Mosier, Philip D.

AU - Zhou, Qibing

AU - Farrell, David

AU - Desai, Umesh R.

PY - 2012/8/9

Y1 - 2012/8/9

N2 - Earlier, we reported on the design of sulfated benzofuran dimers (SBDs) as allosteric inhibitors of thrombin (Sidhu et al. J. Med. Chem.201154 5522-5531). To identify the site of binding of SBDs, we studied thrombin inhibition in the presence of exosite 1 and 2 ligands. Whereas hirudin peptide and heparin octasaccharide did not affect the IC 50 of thrombin inhibition by a high affinity SBD, the presence of full-length heparin reduced inhibition potency by 4-fold. The presence of γ′ fibrinogen peptide, which recognizes Arg93, Arg97, Arg173, Arg175, and other residues, resulted in a loss of affinity that correlated with the ideal Dixon-Webb competitive profile. Replacement of several arginines and lysines of exosite 2 with alanine did not affect thrombin inhibition potency, except for Arg173, which displayed a 22-fold reduction in IC 50. Docking studies suggested a hydrophobic patch around Arg173 as a plausible site of SBD binding to thrombin. The absence of the Arg173-like residue in factor Xa supported the observed selectivity of inhibition by SBDs. Cellular toxicity studies indicated that SBDs are essentially nontoxic to cells at concentrations as high as 250 mg/kg. Overall, the work presents the localization of the SBD binding site, which could lead to allosteric modulators of thrombin that are completely different from all clinically used anticoagulants.

AB - Earlier, we reported on the design of sulfated benzofuran dimers (SBDs) as allosteric inhibitors of thrombin (Sidhu et al. J. Med. Chem.201154 5522-5531). To identify the site of binding of SBDs, we studied thrombin inhibition in the presence of exosite 1 and 2 ligands. Whereas hirudin peptide and heparin octasaccharide did not affect the IC 50 of thrombin inhibition by a high affinity SBD, the presence of full-length heparin reduced inhibition potency by 4-fold. The presence of γ′ fibrinogen peptide, which recognizes Arg93, Arg97, Arg173, Arg175, and other residues, resulted in a loss of affinity that correlated with the ideal Dixon-Webb competitive profile. Replacement of several arginines and lysines of exosite 2 with alanine did not affect thrombin inhibition potency, except for Arg173, which displayed a 22-fold reduction in IC 50. Docking studies suggested a hydrophobic patch around Arg173 as a plausible site of SBD binding to thrombin. The absence of the Arg173-like residue in factor Xa supported the observed selectivity of inhibition by SBDs. Cellular toxicity studies indicated that SBDs are essentially nontoxic to cells at concentrations as high as 250 mg/kg. Overall, the work presents the localization of the SBD binding site, which could lead to allosteric modulators of thrombin that are completely different from all clinically used anticoagulants.

UR - http://www.scopus.com/inward/record.url?scp=84864953109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864953109&partnerID=8YFLogxK

U2 - 10.1021/jm300670q

DO - 10.1021/jm300670q

M3 - Article

C2 - 22788964

AN - SCOPUS:84864953109

VL - 55

SP - 6888

EP - 6897

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 15

ER -